Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.

We developed an experimental model of candidiasis in rabbits with prolonged neutropenia. Rabbits were made neutropenic with cytosine arabinoside (Ara-C) administered through an indwelling silastic catheter that had been surgically implanted in the external jugular vein. Neutropenia was sustained with intravenous Ara-C, and bacterial complications were prevented with parenteral ceftazidime plus ampicillin. Candidiasis was established by intravenously administering Candida albicans or Candida tropicalis (1-2 x 10(5) colony-forming units) and resulted in hepatic and splenic lesions that mimicked those associated with hepatosplenic candidiasis in humans. The kidney proved to be the site most refractory to eradication of Candida spp. and offered a target organ for assessing antifungal therapy. We evaluated amphotericin B, 5-flucytosine, ketoconazole, and rifampin, alone and in combination. Although each agent reduced the colony counts of Candida in the liver, spleen, and lung, the combination of amphotericin B and 5-flucytosine was the only regimen effective in eradicating renal candidiasis.

[1]  T. Shawker,et al.  Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.

[2]  F. Meunier,et al.  In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations , 1986, Antimicrobial Agents and Chemotherapy.

[3]  D. Armstrong,et al.  Distribution and activity of amphotericin B in humans. , 1985, The Journal of infectious diseases.

[4]  B. Wong,et al.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. , 1985, Reviews of infectious diseases.

[5]  M. Weber,et al.  Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. , 1985, Experimental hematology.

[6]  A. Schaffner,et al.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. , 1985, The Journal of infectious diseases.

[7]  G. Bodey Candidiasis in cancer patients. , 1984, The American journal of medicine.

[8]  C. Hawkins,et al.  Fungal infections in the immunocompromised host. , 1984, Clinics in haematology.

[9]  J. Abramson,et al.  Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients. , 1984, Reviews of infectious diseases.

[10]  J. Gold Opportunistic fungal infections in patients with neoplastic disease. , 1984, The American journal of medicine.

[11]  G. Medoff Antifungal action of rifampin. , 1983, Reviews of infectious diseases.

[12]  J. Ernst,et al.  Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. , 1983, Reviews of infectious diseases.

[13]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.

[14]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[15]  R. Hurley Experimental infection with Candida albicans in modified hosts. , 1966, The Journal of pathology and bacteriology.